Pipeline - GenrAb

Lead Candidate

A FULLY HUMAN NEUROPROTECTIVE ANTIBODY

Contains Influential Antibody Sequence Motifs
Identified using the AGS technology confirming critical disease-associated antibody somatic hypermutations
Neuronal Specificity
Exhibits specific binding to neuronal cells and tissues in both animals and humans
Preclinical Efficacy
Demonstrated neuroprotective capabilities in-vitro and a consistent reduction in disability within preclinical models of neurologic disease validated in blinded third-party studies
Crosses the BBB and Enters Cortical Motor Neurons
In a healthy WT model was able to cross the BBB and internalize across multiple layers of cortical neurons
Target Identification and Verification
Unique target identified, verified, and proven colocalization with intercellular stress management machinery
Broad Neuroprotective Impact
Broad neuroprotective capabilities, with proof-of-concept in MS and planned expansion into ALS
Patent Achievement
A US patent has been issued for TGM-010 mAb and its fragments; claims for indicational therapeutic use will be pursued next

GenrAb’s Growing Pipeline

Pipeline

Stage 1
Screening for AGS sequence and neuronal binding
Stage 2
In-vitro efficacy and toxicity analysis

Stage 2
Stage 3
Efficacy validated in multiple preclinical models
Stage 4
Identify and verify molecular target

Stage 4
Stage 5
Determine target biology and therapeutic MoA
Stage 6
mAbs optimized for dosing

Stage 6